Perfusion Medical pioneers IV solutions for tissue perfusion restoration, focusing on revolutionizing the treatment of severe blood loss. Their flagship product, PEG-20k, is designed to increase tissue perfusion, enabling rapid oxygen transfer to oxygen-depleted tissues and organs. This innovative solution targets conditions such as hemorrhagic shock, acute kidney injury (AKI), and cardiac shock, aiming to significantly improve patient survival rates.
Perfusion Medical has achieved notable success, with their PEG-20k solution developed at VCU School of Medicine and supported by substantial Department of Defense funding. The company has published over a dozen studies from leading research institutions, demonstrating the drug's potential to benefit millions of patients. Their advancements in treating ischemic conditions position them as a transformative force in medical treatment for trauma and critical care.
